ZBIO

Quote

Short

News

Articles

Message Board

Zenas BioPharma Inc. (NASDAQ : ZBIO ) News

Zenas BioPharma Inc. (NASDAQ: ZBIO) News Releases

ZBIO News Releases

June 02, 2026 07:05:00 pm

GlobeNewswire

Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine

May 28, 2026 07:05:00 am

GlobeNewswire

Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD

May 19, 2026 07:05:00 am

GlobeNewswire

Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress

May 13, 2026 06:50:00 am

GlobeNewswire

Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor

May 13, 2026 06:06:46 am

SeekingAlpha

Zenas BioPharma GAAP EPS of -$1.46 beats by $0.22

May 13, 2026 06:00:00 am

GlobeNewswire

Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

April 30, 2026 02:36:27 pm

SeekingAlpha

Zenas: 'Strong Buy' On Obexelimab Enhancement And Expected SLE Data Q4 2026

April 30, 2026 09:22:16 am

SeekingAlpha

Zenas BioPharma rises as CEO continues insider purchases

March 27, 2026 05:06:07 am

SeekingAlpha

Biggest stock movers Friday: U, VERI, and more

March 27, 2026 05:06:07 am

SeekingAlpha

Biggest stock movers Friday: Crypto stocks, U, VERI, and more

	Next 10

Subscribe to Our Newsletter

Download The Market Wire News App

Link Market Wire News to Your X Account